Development of a novel drug for transplantation: current results and future perspectives.
Schorlemmer
H U
HU
Institute of Immunopharmacology, Marburg, Germany.
D000480:Alkynes; D000814:Aniline Compounds / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy; D001682:Biological Availability; D003437:Crotonates; D015195:Drug Design; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control; D006085:Graft Survival / Q000187:drug effects / Q000276:immunology; D006086:Graft vs Host Disease / Q000517:prevention & control; D006087:Graft vs Host Reaction / Q000276:immunology; D016027:Heart Transplantation / Q000276:immunology; D006801:Humans; D006885:Hydroxybutyrates / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D007555:Isoxazoles; D009570:Nitriles / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D016038:Skin Transplantation / Q000276:immunology; D014052:Toluidines; D014184:Transplantation, Homologous / Q000276:immunology*
D000480:Alkynes; D000814:Aniline Compounds; D003437:Crotonates; D006885:Hydroxybutyrates; D007166:Immunosuppressive Agents; D007555:Isoxazoles; D009570:Nitriles; D014052:Toluidines; C102911:X 910279; C115284:2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-hepten-6-ynamide; C527525:teriflunomide